PharmaCyte Biotech, Inc. filed a Form D with the Securities and Exchange Commission on 2025-09-04.
PharmaCyte Biotech, Inc. filed a Form D notice of an exempt securities offering with the SEC on September 4, 2025. The filing reports $7M sold. Its industry group is Biotechnology. It names Joshua Silverman (Executive Officer, Director), Carlos Trujillo (Executive Officer), Michael Abecassis (Director) (SEC Form D, September 4, 2025).
Is this your company?
Sell to companies like PharmaCyte Biotech, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-09-04 · the record
Pitching, partnering or investing alongside them? See who really runs and owns PharmaCyte Biotech, Inc.
Free to see. No signup.
More on the people and the money behind PharmaCyte Biotech, Inc., from the filings we hold.
Biotechnology raises by companies based in Nevada, filed within 90 days of this one, largest first.
Get an email when PharmaCyte Biotech, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when PharmaCyte Biotech, Inc. raises, hires or launches. No email unless you switch it on.
Watch PharmaCyte Biotech, Inc. →Get the full cited report on PharmaCyte Biotech, Inc.
What the filing shows about PharmaCyte Biotech, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on PharmaCyte Biotech, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives PharmaCyte Biotech, Inc.'s address as 3960 Howard Hughes Parkway, Suite 500, Las Vegas, NV 89169.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on PharmaCyte Biotech, Inc. See pricing
PharmaCyte Biotech, Inc. is a registered filer with the SEC (CIK 1157075) and has filed since 2025-09-04. 1 filing is on record, the latest on 2025-09-04.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
PharmaCyte Biotech, Inc.'s Form D of 2025-09-04 names Joshua Silverman, Carlos Trujillo, Michael Abecassis and 3 more as its officers, directors or promoters.
Its new offerings report $7M sold across 1 offering, as its own filings state.
Trailing twelve months. 766 filings in Biotechnology, totalled by week.
Joshua Silverman is named as Executive Officer and Director on the Form D that PharmaCyte Biotech, Inc. filed with the SEC on 4 September 2025, one of 6 people that filing names.
Carlos Trujillo is named as Executive Officer on the Form D that PharmaCyte Biotech, Inc. filed with the SEC on 4 September 2025, one of 6 people that filing names.
Michael Abecassis is named as Director on the Form D that PharmaCyte Biotech, Inc. filed with the SEC on 4 September 2025, one of 6 people that filing names.
Robert Weinstein is named as Director on the Form D that PharmaCyte Biotech, Inc. filed with the SEC on 4 September 2025, one of 6 people that filing names.
Walker Wayne is named as Director on the Form D that PharmaCyte Biotech, Inc. filed with the SEC on 4 September 2025, one of 6 people that filing names.
Jonathan Schechter is named as Director on the Form D that PharmaCyte Biotech, Inc. filed with the SEC on 4 September 2025, one of 6 people that filing names.
6 people named on the filing — 2 holding an executive role and 4 as directors only.
Named as of the 2025-09-04 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about PharmaCyte Biotech, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on PharmaCyte Biotech, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on PharmaCyte Biotech, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist PharmaCyte Biotech, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind PharmaCyte Biotech, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for PharmaCyte Biotech, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in Las Vegas
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/pharmacyte-biotech-inc-form-d-25000001